INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

INmune Bio (NASDAQ: INMB ) has recently announced that it will be seeking approval of CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa [RDEB] after favorable investigator-initiated trial results. CORDStrom was out of focus of investors. The FDA recentlyI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. ...